A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
This study is exploring whether a new medicine, spesolimab, can help adults with a skin condition called pyoderma gangrenosum (PG). The main goal is to see if spesolimab leads to the healing of PG ulcers. Participants will receive either spesolimab or a placebo (a dummy medicine) through a drip, along with steroid tablets initially. The study runs in two parts, with treatment assigned by chance. Doctors will regularly check participants' skin, health, and any side effects over about 1.5 years. The results will help determine if spesolimab is an effective treatment for PG.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
You might be reading this because you or someone you know has pyoderma gangrenosum (PG), a difficult skin condition. This study is looking into a new medicine called spesolimab. The main idea is to find out if spesolimab can help heal the ulcers (open sores) that are a common problem with PG. If it works, it could offer a new way to treat this condition.
The study involves adults who have ulcerative PG, meaning they have ulcers on their skin. The ulcers need to be a certain size to join the study. Researchers want to compare spesolimab with a placebo, which looks like the real medicine but doesn't contain any active ingredients. This helps them truly understand if the medicine itself is making a difference.
By taking part, you would be helping doctors and scientists learn more about PG and how to treat it. Every participant's experience provides valuable information, bringing us closer to better treatments for everyone with this condition.
النقاط الرئيسية
- This study tests if spesolimab helps heal pyoderma gangrenosum (PG) ulcers.
- It involves adults with specific types of PG ulcers.
- You might receive spesolimab or a placebo, plus steroid tablets initially.
- Treatment is given as a drip every four weeks.
- The study lasts about 1.5 years with regular clinic visits.
- Your participation helps to advance PG treatment research.
من قد يكون مؤهلاً؟
To be able to join this study, you need to be an adult, aged 18 or over. You must also have a clear diagnosis of ulcerative pyoderma gangrenosum (PG), which means you have ulcers on your skin related to this condition. These ulcers need to be a certain size, not too small and not too large (between 5 and 80 square centimetres).
Your PG ulcer should also have been diagnosed within the last six months, though some older, active ulcers might be considered. It's important that your ulcers are not infected when you start the study. Also, if you are a woman who could become pregnant, you'll need to agree to use effective birth control throughout the study.
You cannot join if you have other types of skin sores that are not PG, or if your PG ulcers are very large. Also, if your ulcers are chronic and don't respond to usual treatments that calm the immune system, you might not be suitable for this particular study.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Have you been diagnosed with ulcerative pyoderma gangrenosum (PG)?
- Do you have at least one PG ulcer between 5 and 80 square centimetres in size?
- Is your PG ulcer not currently infected?
- If you are a woman, are you willing to use effective birth control during the study?
- Do you not have other types of skin sores that are not PG?
ماذا يتضمن المشاركة؟
If you decide to join this study, it will last for about 1.5 years. During this time, you'll visit the study clinic 20 times. At these visits, doctors will carefully check your skin – especially your PG ulcers – to see how they are healing. They will also keep a close eye on your general health and write down any side effects you might experience.
In the study, you'll receive either the medicine spesolimab or a placebo (a dummy medicine) through a drip into your arm. This drip will be given every four weeks. For the first eight weeks, all participants will also take steroid tablets by mouth. The study involves two parts, and the treatment you receive will be decided by chance, meaning it's random.
If you have open ulcers, during the second part of the study, you will receive spesolimab. If your ulcers have healed, you might get either spesolimab or the placebo. You can also withdraw from the study at any time.
المخاطر والفوائد المحتملة
Locations (96)
- جامعة ألاباما في برمنغهامالرمز البريدي المؤكدبرمنغهام، الولايات المتحدة· التوظيف
- Medical Dermatology Specialists Phoenixالرمز البريدي المؤكدفينيكس، الولايات المتحدة· التوظيف
- جامعة كاليفورنيا إيرفينالرمز البريدي المؤكدإرفاين، الولايات المتحدة· التوظيف
- جامعة مياميالرمز البريدي المؤكدميامي، الولايات المتحدة· التوظيف
- جامعة جنوب فلوريداالرمز البريدي المؤكدتامبا، الولايات المتحدة· التوظيف
- Ada West Researchالرمز البريدي المؤكدMeridian, United States· لم يبدأ التوظيف بعد
- Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995الرمز البريدي المؤكدإنديانابوليس، الولايات المتحدة· التوظيف
- مستشفى بريجهام والنساءالرمز البريدي المؤكدبوسطن، الولايات المتحدة· التوظيف
- University of Michiganالرمز البريدي المؤكدآن آربر، الولايات المتحدة· التوظيف
- Dartmouth Hitchcock Clinics Heater Roadالرمز البريدي المؤكدLebanon, United States· التوظيف
- Dermatology at Lake Successالرمز البريدي المؤكدليك سكسيس، الولايات المتحدة· التوظيف
- كلية إيكان للطب في جبل سيناءالرمز البريدي المؤكدنيويورك، الولايات المتحدة· التوظيف
أسئلة شائعة
What is pyoderma gangrenosum (PG)?
Pyoderma gangrenosum is a rare skin condition that causes painful sores or ulcers, especially on the legs. It's not an infection but is thought to be an autoimmune problem.
ما هو الدواء الوهمي؟
A placebo is a substance that looks exactly like the real medicine but contains no active ingredients. It helps researchers compare the effects of the actual drug against no treatment.
Why do some people get a placebo?
Giving some participants a placebo helps doctors understand if the new medicine is truly working or if improvements are due to other factors. This makes the study results more reliable.
كم من الوقت سأكون في الدراسة؟
You will be in this study for approximately 1.5 years (about 18 months).
هل يمكنني التوقف عن المشاركة في الدراسة في أي وقت؟
Yes, you have the right to withdraw from the study at any point, for any reason, without it affecting your medical care.
كيفية معرفة المزيد
Boehringer Ingelheim
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.